Secure Better Patient & Business Outcomes With Actionable, Tangible, Value-Adding Strategies To Enhance Patient Centricity & Engagement & Embed Patients At The Heart Of Decision Making
Collaborative Engagement & Experience Strategies Which Inform Clinical Trial Design, Drug Development & Strategic Business Direction With Early Patient Involvement, Insights & Feedback, Leverage Digital & Technology Innovations Compliantly & Enhance Patient Safety & Journey. A One-Day Conference & Networking Event, 21st May 2019, The Hallam Conference Centre, Central London
08:30 Registration, Morning Coffee & Objective Setting
09:00 GIC Welcome & Morning Chair’s Opening Remarks
Chief Medical Officer
EMBEDDING PATIENTS AT THE HEART OF DECISION MAKING
09.15 Truly Embedding Patient Centricity Into Business Decision Making With Meaningful Patient Involvement For Tangibly Enriched Patient & Business Outcomes
- Recognising the gaps between intent and action: taking a good look at internal strategies to determine where increased patient input can make the most impact on patient outcomes and commercial success; bring the patient voice into the organisation
- Demonstrating a financial payoff to further motivate internal departments to involve patients in decision making and convince them of the importance of patient-pharma collaboration
- How can we overcome industry hurdles such as tight regulations, communications barriers and internal apathy to deliver real examples of commitment, change and tangible outputs as well as a commitment to progress and more meaningful patient involvement?
Executive Vice President, Neurology Patient Value Head
EARLY PATIENT INVOLVEMENT
09.35 Clinical Trial Design & Drug Development: Recruit & Action Patient Feedback On Trial Design For More Effective R&D & Better Patient Outcomes & Experiences
- Innovative methods of creating awareness and recruiting patients into early-stage R&D for crucial patient feedback which improves trial experience and effectiveness
- Bridging the gap between patients, industry and stakeholder insights and needs and real-world evidence for meaningful, multi-stakeholder drug development processes
- Practical steps to feed patient-reported outcomes and insights into development strategies which build patient value into design
- Closing the loop – how can pharma brands build a community and better relay the outcomes of a clinical trial to the patient volunteers?
09.35 Perspective One:
Oncology Medical Affairs Head
09.55 Perspective Two:
Vice President, Clinical Development, Rare Diseases, Global R&D
THE PATIENT PERSPECTIVE - Q&A PANEL
10.15 The Patient Perspective: What Can Pharma Do To Enable More Meaningful & Effective Patient-Pharma Collaboration?
- Pharma want to know how they can better create awareness, engage patients and feed patient feedback into the decision making of the company. What do you think they should be doing differently?
- The patient point of view – what in the system do you want to challenge and what do you and the patient community expect from the pharma industry?
- The future: how do you think long-term pharma-patient relationships could be improved? What measures would you like to see put in place?
Clinical & Operations Director
National Osteoporosis Society
Head of Patient Communication & Involvement
CEO and Founder
Global Product Director (Customer Labs)
Patient Insights Leader
10.45 Morning Refreshment Break With Informal Networking
Breakout Groups By Therapy Area:
A: Cancer Care
B: Mental Health
C: Long-Term Conditions
D: Rare Diseases
F: Other Breakouts By Area
PATIENT & PHARMA COLLABORATION CASE STUDY - Q&A PANEL
11.15 Our Story: Real-Life Patient-Pharma Collaboration – Overcoming Barriers For Meaningful, Value-Adding Relationships Which Positively Impact Patient Outcomes & Pharma’s Bottom Line
- How our relationship started: from initial contact to long-term partnership, how did our relationship evolve and what helped it flourish?
- How did we enable this collaboration to be effective? What did we both need and how did we overcome hurdles and manage expectations to align our shared objectives?
- Who else did we need? From third parties, regulatory boards and HCPs, how did we motivate and involve the right people?
- What have we achieved? Evidence of value created for patients, the healthcare system and pharma
Director, Patient Advocacy & Strategic Partnerships
PLUS! Patient Partner Speaker To Be Confirmed
11.35 Leveraging Technology For Optimal Patient Engagement
- Learn about innovative, technological solutions that can be implemented in order to eliminate patient engagement barriers
- Discuss the use of these tools that foster learnings, deeper insights, and more timely feedback
- Explore real world case studies
SVP Business Partnerships
COLLABORATION WITH KEY STAKEHOLDERS - INSIGHTS PANEL
12.05 Exploring Blockers To Multi-Stakeholder Collaboration: How Can We All Align Behind The Patient?
There are many reasons why it can be difficult to have meaningful patient input within pharma. This panel is bringing together key stakeholders within the industry to explore how multi-stakeholder collaboration can be approached more efficiently to uncover tangible ways of moving forwards together.
Liesbeth De Boer-Oosterhuis
Manager Alliance Development & Patient Advocacy
ABPI Code Engagement
Further speakers to be announced. Please check the website for further details.
12.35 Lunch For Speakers, Delegates & Partners
13.05 Informal Peer-To-Peer Discussion Zones
A) Patient Experience
Dr Mate A. Balazs
Country Head - Patient Safety
B) Patient Advocacy Group Perspective - Clinical Trials
Dr Helen Bulbeck
Director of Services & Policy
Brainstrust - the brain cancer people
Head of Clinical Operations & Data Management, Centre for Drug Discovery
C) Pharma Perspective - Patient Experience & Clinical Trial Design
Patient Insights Leader
E) Patient Recruitment
13.35 Afternoon Chair’s Opening Remarks
Director of Clinical Services
ENHANCING PATIENT JOURNEYS, INFORMATION & FEEDBACK - CASE STUDY
13.50 Challenges In Providing Accurate Information To Patients, With An Insight Into Data Use
- How are patients seeking information? What tools are out there today to handle patient data and information to provide the best possible experiences?
- Innovative and effective methodologies to collect accurate patient data and translate patient feedback and data into actionable insights to improve patient services
- What should change to significantly improve the value and quality of clear information to patients?
Public Policy & Patient Engagement Director, Europe, Russia, Africa, Middle East
PATIENT ENGAGEMENT THROUGH DIGITAL & TECH - DOUBLE PERSPECTIVE
14.10 Leveraging New Technologies Compliantly To Improve Patient Experience For Interactive Communications Which Engage Patients Around Their Healthcare
- Exploring the potential impact and long-term implications of new technologies on patient care: what are the innovations we need to sit up and listen to, what do patients want and how can we make a real difference with quite simple tech and tools?
- Applying digital channels and technologies to enhance patient recruitment, increase patient engagement through clinical trials and accessing information about their treatment
- Identifying opportunities new tech offers to collect valuable and intangible data such as emotions, reactions side effects, adverse event reporting and ineffective drugs during trials and with drugs on the market
- Exploring the implications of the HTA reform
14:10 Perspective One
Consumer Planning & Insights
Walgreens Boots Alliance
14:30 Perspective Two
VP Market Access, Public A airs & Patient Advocacy, Europe & Canada
15.25 Afternoon Refreshment Break With Informal Networking
VALUE-ADDING PATIENT EXPERIENCES
15.50 Determining The Impact Of Patient-Pharma Collaboration & Value Added To The Patient & The Business
- How do you tangibly measure value-added? How do you measure how valuable and effective patient engagement is?
- Patient reported outcomes - what do patients consider value adding?
- Creating value is great – but, how can you create value at scale?
Patient Experience & Service Director
16.10 Significant Measures Pharma Can Take To Further Ensure Patient Safety Throughout The Patient Journey
- Ensuring it is patient safety at the forefront of decision making
- Refining your patient safety strategies in the real world where increased complexities, comorbidities and other drugs ramp up the chances of an adverse reaction
- Better engaging and communicating with the patient around their treatment by using technologies to educate them on reporting and their own conditions
- Understanding and consulting on patient preference and going beyond patient experience to decide risk-reward profiles
16.10 Perspective One
Principal, Pharmacovigilance Processes & Partnerships
OVERCOMING BARRIERS TO PATIENT CENTRICITY
16.50 It’s All Very Well Talking The Talk But How Can Pharma Actually Take Steps To Progress Their Patient Strategies, Improve Patient Outcomes & Further The Business?
How can you overcome barriers to:
- Health-check your own activities and ensure your organisation is really patient-centric - then readdress strategies if necessary?
- Adapt to different patient behaviours, engagement and motivation levels?
- Enhance patient communications and engage better with the patient on decision making?
- Successfully execute initiatives in view of regulation?
Head of Patient Communication & Involvement
European Lead, Patient Innovation
Associate Director Global Patient Recruitment & Retention Strategist
Head of Medical Affairs Oncology
17.00 Co-Chairs’ Closing Remarks & Official Close Of Conference